… than when targeting only girls aged 9–18 years. Current evidence does not … cost-effectiveness
of 9-valent vaccine compared to the older HPV vaccines as the price for 9-valent vaccine …

… programs, hence these countries may have less impetus for cost-effectiveness studies to
inform local decision making as priorities are driven by external considerations. …

… analysis, the 9-valent HPV vaccine was not cost-effective for … the quadrivalent or the bivalent
vaccine, which remained so in … suggest that the price of the 9-valent HPV vaccine needs to …

… It is important to mention that our results may underestimate the additional benefits of the
nine-valent vaccine vaccination on CIN. In the study from Hartwig et al. results showed that the …

… We present the first cost-effectiveness analysis of the implementation of a vaccination
program with the new 9-valent HPV vaccine extended to boys in Germany. All analyses were …

… the potential risks and benefits of reducing recommended HPV vaccination schedules
from 3 to 2 doses. Our results suggest that 2-dose 9-valent vaccination would have to provide …

… of vaccine costs for which the 9-valent vaccine would be cost-effective in comparison to the
current vaccines in … This analysis estimates a range of added vaccine costs within which HPV …

… nonavalent HPV vaccine (6/11/16/18/31/33/45/52/58), this analysis aims … vaccination
strategies performed with the 9-valent vaccine in the current study were all found to be cost-effective …

… of this analysis was to estimate the potential impact and cost-… and included all vaccination
costs, relevant direct medical costs, and … to who incurred the costs or who received the benefits. …

… 9-valent vaccine is more cost-effective (cost per QALY gained of $12 208 for the 9-valent
vaccine vs cost … Because the 9-valent vaccine was only recently approved, research evidence is …